<?xml version="1.0" encoding="UTF-8"?>
<p id="p0540">Notwithstanding, the dangers of using both drugs as anti-coronavirus therapy have been shown by Taccone et al.
 <xref rid="b1305" ref-type="bibr">
  <sup>261</sup>
 </xref> who criticized the strategy employed by Gautret et al.
 <xref rid="b1300" ref-type="bibr">
  <sup>260</sup>
 </xref>. In fact, Taccone et al.
 <xref rid="b1305" ref-type="bibr">
  <sup>261</sup>
 </xref> claim that HCQ clinical data obtained by Gautret et al.
 <xref rid="b1300" ref-type="bibr">
  <sup>260</sup>
 </xref> are far from convincing due to the small size of the sample (only 20 patients) given HCQ (six of which also received azithromycin) and to the short observation time (6â€¯days) for all 16 control patients included in the final analysis. In addition, the absence of a randomized investigation and no report on adverse effects during clinical evolution raised concerns about the outcomes. Taccone et al.
 <xref rid="b1305" ref-type="bibr">
  <sup>261</sup>
 </xref> also criticized clinical outcomes that were misinterpreted and invalid in order to highlight the need for prospective, randomized, placebo-controlled and adequate clinical trials. The authors sustain the inadequacy of considering drugs with promising 
 <italic>in-vitro</italic> and/or 
 <italic>in-silico</italic> results as more beneficial than harmful.
</p>
